Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on Autolus Therapeutics (AUTL) Presents Positive Long-Term Obe-cel Data at EHA 2025 - MSN

Autolus Therapeutics (AUTL) Presents Positive Long-Term Obe-cel Data at EHA 2025  MSN

Autolus Therapeutics (AUTL) Presents Positive Long-Term Obe-cel Data at EHA 2025 - MSN

Click here to get full coverage on Autolus Therapeutics plc (AUTL): Analysts See 697% Upside Potential - Yahoo Finance

Autolus Therapeutics plc (AUTL): Analysts See 697% Upside Potential  Yahoo Finance

Autolus Therapeutics plc (AUTL): Analysts See 697% Upside Potential - Yahoo Finance

Click here to get full coverage on AUTOLUS THERAPEUTICS Earnings Results: $AUTL Reports Quarterly Earnings - Nasdaq

AUTOLUS THERAPEUTICS Earnings Results: $AUTL Reports Quarterly Earnings  Nasdaq

AUTOLUS THERAPEUTICS Earnings Results: $AUTL Reports Quarterly Earnings - Nasdaq

Click here to get full coverage on New Clinical Data: Autolus Cancer Therapy Achieves 3.5-Year Remission Without Additional Treatment - Stock Titan

New Clinical Data: Autolus Cancer Therapy Achieves 3.5-Year Remission Without Additional Treatment  Stock Titan

New Clinical Data: Autolus Cancer Therapy Achieves 3.5-Year Remission Without Additional Treatment - Stock Titan

Click here to get full coverage on Autolus Therapeutics gets EU endorsement for leukemia treatment - Seeking Alpha

Autolus Therapeutics gets EU endorsement for leukemia treatment  Seeking Alpha

Autolus Therapeutics gets EU endorsement for leukemia treatment - Seeking Alpha

Click here to get full coverage on Shareholders in Autolus Therapeutics (NASDAQ:AUTL) have lost 79%, as stock drops 11% this past week - simplywall.st

Shareholders in Autolus Therapeutics (NASDAQ:AUTL) have lost 79%, as stock drops 11% this past week  simplywall.st

Shareholders in Autolus Therapeutics (NASDAQ:AUTL) have lost 79%, as stock drops 11% this past week - simplywall.st

Click here to get full coverage on Needham Reiterates a Buy Rating on Autolus Therapeutics (AUTL), Keeps the PT at $10 - MSN

Needham Reiterates a Buy Rating on Autolus Therapeutics (AUTL), Keeps the PT at $10  MSN

Needham Reiterates a Buy Rating on Autolus Therapeutics (AUTL), Keeps the PT at $10 - MSN

Click here to get full coverage on Autolus Leadership to Share Strategic Updates at Three Elite Healthcare Investor Conferences - Stock Titan

Autolus Leadership to Share Strategic Updates at Three Elite Healthcare Investor Conferences  Stock Titan

Autolus Leadership to Share Strategic Updates at Three Elite Healthcare Investor Conferences - Stock Titan

Click here to get full coverage on Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market (AUTL) - Seeking Alpha

Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market (AUTL)  Seeking Alpha

Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market (AUTL) - Seeking Alpha

Click here to get full coverage on Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress - Stock Titan

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress  Stock Titan

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress - Stock Titan

Click here to get full coverage on Why Autolus Therapeutics (AUTL) Is One of the Best Biotech Penny Stocks to Invest in Now? - Yahoo Finance

Why Autolus Therapeutics (AUTL) Is One of the Best Biotech Penny Stocks to Invest in Now?  Yahoo Finance

Why Autolus Therapeutics (AUTL) Is One of the Best Biotech Penny Stocks to Invest in Now? - Yahoo Finance

Click here to get full coverage on Autolus Therapeutics Q1 Earnings Preview: Key T Cell Therapy Commercial Updates Expected May 8 - Stock Titan

Autolus Therapeutics Q1 Earnings Preview: Key T Cell Therapy Commercial Updates Expected May 8  Stock Titan

Autolus Therapeutics Q1 Earnings Preview: Key T Cell Therapy Commercial Updates Expected May 8 - Stock Titan

Click here to get full coverage on Is Autolus Therapeutics plc (AUTL) the Best UK Growth Stock to Buy Now? - Yahoo Finance

Is Autolus Therapeutics plc (AUTL) the Best UK Growth Stock to Buy Now?  Yahoo Finance

Is Autolus Therapeutics plc (AUTL) the Best UK Growth Stock to Buy Now? - Yahoo Finance

Click here to get full coverage on Autolus Triples Cash to $588M, Secures 85% Coverage for FDA-Approved AUCATZYL - Stock Titan

Autolus Triples Cash to $588M, Secures 85% Coverage for FDA-Approved AUCATZYL  Stock Titan

Autolus Triples Cash to $588M, Secures 85% Coverage for FDA-Approved AUCATZYL - Stock Titan

Click here to get full coverage on Autolus to Unveil New Lupus Trial Data and Pipeline Expansion Plans at R&D Event - Stock Titan

Autolus to Unveil New Lupus Trial Data and Pipeline Expansion Plans at R&D Event  Stock Titan

Autolus to Unveil New Lupus Trial Data and Pipeline Expansion Plans at R&D Event - Stock Titan

Click here to get full coverage on Autolus Clinical Trial Shows Breakthrough 50% Response in Lupus Patients, Plans MS Treatment Launch - Stock Titan

Autolus Clinical Trial Shows Breakthrough 50% Response in Lupus Patients, Plans MS Treatment Launch  Stock Titan

Autolus Clinical Trial Shows Breakthrough 50% Response in Lupus Patients, Plans MS Treatment Launch - Stock Titan

Click here to get full coverage on When Will Autolus Report Q4 Earnings? Key Date for Cell Therapy Leader - Stock Titan

When Will Autolus Report Q4 Earnings? Key Date for Cell Therapy Leader  Stock Titan

When Will Autolus Report Q4 Earnings? Key Date for Cell Therapy Leader - Stock Titan

Click here to get full coverage on Industry Analysts Just Upgraded Their Autolus Therapeutics plc (NASDAQ:AUTL) Revenue Forecasts By 12% - simplywall.st

Industry Analysts Just Upgraded Their Autolus Therapeutics plc (NASDAQ:AUTL) Revenue Forecasts By 12%  simplywall.st

Industry Analysts Just Upgraded Their Autolus Therapeutics plc (NASDAQ:AUTL) Revenue Forecasts By 12% - simplywall.st

Click here to get full coverage on Further weakness as Autolus Therapeutics (NASDAQ:AUTL) drops 21% this week, taking five-year losses to 71% - Yahoo Finance

Further weakness as Autolus Therapeutics (NASDAQ:AUTL) drops 21% this week, taking five-year losses to 71%  Yahoo Finance

Further weakness as Autolus Therapeutics (NASDAQ:AUTL) drops 21% this week, taking five-year losses to 71% - Yahoo Finance

Click here to get full coverage on AUTL stock touches 52-week low at $1.53 amid market challenges - Investing.com

AUTL stock touches 52-week low at $1.53 amid market challenges  Investing.com

AUTL stock touches 52-week low at $1.53 amid market challenges - Investing.com

Click here to get full coverage on Why Autolus Therapeutics plc (AUTL) is the Penny Stock with the Biggest Upside Potential According to Analysts - Yahoo Finance

Why Autolus Therapeutics plc (AUTL) is the Penny Stock with the Biggest Upside Potential According to Analysts  Yahoo Finance

Why Autolus Therapeutics plc (AUTL) is the Penny Stock with the Biggest Upside Potential According to Analysts - Yahoo Finance

Click here to get full coverage on Autolus Therapeutics Will Remain Depressed For A While (NASDAQ:AUTL) - Seeking Alpha

Autolus Therapeutics Will Remain Depressed For A While (NASDAQ:AUTL)  Seeking Alpha

Autolus Therapeutics Will Remain Depressed For A While (NASDAQ:AUTL) - Seeking Alpha

Click here to get full coverage on Autolus Therapeutics plc (AUTL): A Bull Case Theory - Yahoo Finance

Autolus Therapeutics plc (AUTL): A Bull Case Theory  Yahoo Finance

Autolus Therapeutics plc (AUTL): A Bull Case Theory - Yahoo Finance

Click here to get full coverage on Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy (NASDAQ:AUTL) - Seeking Alpha

Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy (NASDAQ:AUTL)  Seeking Alpha

Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy (NASDAQ:AUTL) - Seeking Alpha

Click here to get full coverage on Is Autolus Therapeutics (NASDAQ:AUTL) A Risky Investment? - simplywall.st

Is Autolus Therapeutics (NASDAQ:AUTL) A Risky Investment?  simplywall.st

Is Autolus Therapeutics (NASDAQ:AUTL) A Risky Investment? - simplywall.st

Click here to get full coverage on Autolus Therapeutics Releases UK Annual Report 2024 - TipRanks

Autolus Therapeutics Releases UK Annual Report 2024  TipRanks

Autolus Therapeutics Releases UK Annual Report 2024 - TipRanks

Click here to get full coverage on Autolus Therapeutics to Present R&D Update April 23 - TipRanks

Autolus Therapeutics to Present R&D Update April 23  TipRanks

Autolus Therapeutics to Present R&D Update April 23 - TipRanks

Click here to get full coverage on Autolus Therapeutics plc (AUTL) reports earnings - Quartz

Autolus Therapeutics plc (AUTL) reports earnings  Quartz

Autolus Therapeutics plc (AUTL) reports earnings - Quartz

Click here to get full coverage on Autolus Leukemia Treatment Scores Major EU Win: 77% Response Rate Impresses CHMP After FDA Approval - Stock Titan

Autolus Leukemia Treatment Scores Major EU Win: 77% Response Rate Impresses CHMP After FDA Approval  Stock Titan

Autolus Leukemia Treatment Scores Major EU Win: 77% Response Rate Impresses CHMP After FDA Approval - Stock Titan

Click here to get full coverage on AUTL stock touches 52-week low at $1.87 amid market challenges - Investing.com

AUTL stock touches 52-week low at $1.87 amid market challenges  Investing.com

AUTL stock touches 52-week low at $1.87 amid market challenges - Investing.com

Click here to get full coverage on Autolus Therapeutics Passes All AGM Resolutions - TipRanks

Autolus Therapeutics Passes All AGM Resolutions  TipRanks

Autolus Therapeutics Passes All AGM Resolutions - TipRanks

Click here to get full coverage on Autolus Therapeutics Directors Announce Departure Plans - TipRanks

Autolus Therapeutics Directors Announce Departure Plans  TipRanks

Autolus Therapeutics Directors Announce Departure Plans - TipRanks

Click here to get full coverage on Autolus Therapeutics (AUTL) Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblast - StreetInsider

Autolus Therapeutics (AUTL) Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblast  StreetInsider

Autolus Therapeutics (AUTL) Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblast - StreetInsider

Click here to get full coverage on Autolus Therapeutics Secures Critical UK Approval for Breakthrough Leukemia Therapy—What Investors Need to Know - AInvest

Autolus Therapeutics Secures Critical UK Approval for Breakthrough Leukemia Therapy—What Investors Need to Know  AInvest

Autolus Therapeutics Secures Critical UK Approval for Breakthrough Leukemia Therapy—What Investors Need to Know - AInvest

Click here to get full coverage on AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market - Seeking Alpha

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market  Seeking Alpha

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market - Seeking Alpha

Click here to get full coverage on Autolus Therapeutics Reports Q1 2025 Financial Results - TipRanks

Autolus Therapeutics Reports Q1 2025 Financial Results  TipRanks

Autolus Therapeutics Reports Q1 2025 Financial Results - TipRanks

Click here to get full coverage on Autolus Therapeutics plc (AUTL): The Best Multibagger Penny Stock of 2025? - Yahoo Finance

Autolus Therapeutics plc (AUTL): The Best Multibagger Penny Stock of 2025?  Yahoo Finance

Autolus Therapeutics plc (AUTL): The Best Multibagger Penny Stock of 2025? - Yahoo Finance

Click here to get full coverage on Autolus Therapeutics Announces Leadership Transition in Finance - TipRanks

Autolus Therapeutics Announces Leadership Transition in Finance  TipRanks

Autolus Therapeutics Announces Leadership Transition in Finance - TipRanks

Click here to get full coverage on Autolus Therapeutics plc SEC 10-K Report - TradingView

Autolus Therapeutics plc SEC 10-K Report  TradingView

Autolus Therapeutics plc SEC 10-K Report - TradingView

Click here to get full coverage on Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - TradingView

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025  TradingView

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - TradingView

Click here to get full coverage on Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case - Seeking Alpha

Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case  Seeking Alpha

Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case - Seeking Alpha

Click here to get full coverage on Autolus Therapeutics earnings matched, revenue topped estimates - Investing.com

Autolus Therapeutics earnings matched, revenue topped estimates  Investing.com

Autolus Therapeutics earnings matched, revenue topped estimates - Investing.com

Click here to get full coverage on Syncona Portfolio Ltd Expands Stake in Autolus Therapeutics PLC - GuruFocus

Syncona Portfolio Ltd Expands Stake in Autolus Therapeutics PLC  GuruFocus

Syncona Portfolio Ltd Expands Stake in Autolus Therapeutics PLC - GuruFocus

Click here to get full coverage on Autolus Therapeutics Q1 2025: Unraveling Key Contradictions in Revenue, Tariffs, and Manufacturing Success - AInvest

Autolus Therapeutics Q1 2025: Unraveling Key Contradictions in Revenue, Tariffs, and Manufacturing Success  AInvest

Autolus Therapeutics Q1 2025: Unraveling Key Contradictions in Revenue, Tariffs, and Manufacturing Success - AInvest

Click here to get full coverage on Autolus Therapeutics: Positive Momentum Amid Financial Challenges - TipRanks

Autolus Therapeutics: Positive Momentum Amid Financial Challenges  TipRanks

Autolus Therapeutics: Positive Momentum Amid Financial Challenges - TipRanks

Click here to get full coverage on FMR LLC's Strategic Acquisition of Autolus Therapeutics PLC Shar - GuruFocus

FMR LLC's Strategic Acquisition of Autolus Therapeutics PLC Shar  GuruFocus

FMR LLC's Strategic Acquisition of Autolus Therapeutics PLC Shar - GuruFocus

Click here to get full coverage on Autolus Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

Autolus Therapeutics to Participate in Upcoming Investor Conferences  The Manila Times

Autolus Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

Click here to get full coverage on Autolus stock plunges to 52-week low of $1.23 amid market challenges - Investing.com UK

Autolus stock plunges to 52-week low of $1.23 amid market challenges  Investing.com UK

Autolus stock plunges to 52-week low of $1.23 amid market challenges - Investing.com UK

Click here to get full coverage on Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates - The Manila Times

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates  The Manila Times

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates - The Manila Times

Click here to get full coverage on Autolus Therapeutics PLC reports results for the quarter ended December 31 - Earnings Summary - TradingView

Autolus Therapeutics PLC reports results for the quarter ended December 31 - Earnings Summary  TradingView

Autolus Therapeutics PLC reports results for the quarter ended December 31 - Earnings Summary - TradingView

Click here to get full coverage on Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - The Manila Times

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates  The Manila Times

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - The Manila Times

Click here to get full coverage on Autolus Therapeutics Provides Business Updates and 2025 Overview - The Manila Times

Autolus Therapeutics Provides Business Updates and 2025 Overview  The Manila Times

Autolus Therapeutics Provides Business Updates and 2025 Overview - The Manila Times

Click here to get full coverage on Needham Reiterates Autolus Therapeutics plc - ADR (AUTL) Buy Recommendation - Nasdaq

Needham Reiterates Autolus Therapeutics plc - ADR (AUTL) Buy Recommendation  Nasdaq

Needham Reiterates Autolus Therapeutics plc - ADR (AUTL) Buy Recommendation - Nasdaq

Click here to get full coverage on Autolus Therapeutics plc - ADR (AUTL) Price Target Increased by 9.15% to 8.14 - Nasdaq

Autolus Therapeutics plc - ADR (AUTL) Price Target Increased by 9.15% to 8.14  Nasdaq

Autolus Therapeutics plc - ADR (AUTL) Price Target Increased by 9.15% to 8.14 - Nasdaq

Click here to get full coverage on BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect An Acquisition (NASDAQ:BNTX) - Seeking Alpha

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect An Acquisition (NASDAQ:BNTX)  Seeking Alpha

Autolus Therapeutics Ltd (AUTL)

Price Chart

Key Statistics

Technicals

About AUTL

Latest News

Autolus Therapeutics (AUTL) Presents Positive Long-Term Obe-cel Data at EHA 2025 - MSN

Autolus Therapeutics plc (AUTL): Analysts See 697% Upside Potential - Yahoo Finance

AUTOLUS THERAPEUTICS Earnings Results: $AUTL Reports Quarterly Earnings - Nasdaq

Advanced Charts

Top Gainers

Top Losers